polio vaccine

polio vaccine
Title	Polio Vaccine
Type	Killed/Live
Target	Poliovirus
Routes of administration	Intramuscular injection, Oral drops
ATC prefix	J07
ATC suffix	BF01, BF03

polio vaccine is a critical immunization used to prevent poliomyelitis, a debilitating viral disease. The development of effective vaccines in the mid-20th century marked a monumental achievement in public health and virology. Today, these vaccines are the cornerstone of a global initiative spearheaded by the World Health Organization aimed at total disease eradication.

History and development

The urgent quest for a preventive agent intensified following severe epidemics in the United States and Europe during the early 20th century. Key foundational work was conducted at institutions like the University of Pittsburgh and the Children's Hospital Boston. Researcher Jonas Salk developed the first licensed vaccine, an inactivated preparation, with large-scale field trials famously involving millions of children, known as the Polio Pioneers. Shortly thereafter, Albert Sabin pioneered a live-attenuated oral vaccine, which underwent extensive testing internationally, including in the Soviet Union and Mexico. The rivalry between the approaches of Salk and Sabin shaped subsequent vaccination policies worldwide for decades.

Types of polio vaccine

Two main formulations are utilized globally. The inactivated poliovirus vaccine, known as IPV, contains virus particles killed by methods such as formalin and is administered via injection. The oral poliovirus vaccine, or OPV, uses weakened but live viruses and is given as oral drops. OPV exists in several formulations, including trivalent versions and more recent monovalent and bivalent types targeting specific serotypes. A novel oral polio vaccine type 2, utilizing genetically stabilized vaccine virus, has been deployed to address outbreaks linked to vaccine-derived strains.

Administration and schedule

Immunization schedules are determined by national health authorities like the Centers for Disease Control and Prevention and the National Health Service. In many countries, IPV is given as a series of intramuscular injections, typically at ages two months, four months, and between six to eighteen months, with a booster dose before school entry. OPV is often used in mass vaccination campaigns, sometimes called National Immunization Days, in endemic regions. The strategic use of both vaccines is coordinated by entities such as the Global Polio Eradication Initiative.

Efficacy and impact

Both vaccines are highly effective at inducing protective immunity against paralytic disease. Widespread vaccination has led to the elimination of wild poliovirus from entire continents, including the Americas, certified free in 1994, and Europe. Surveillance data from organizations like the WHO show a reduction of global cases from hundreds of thousands annually to only a handful confined to specific regions like parts of Afghanistan and Pakistan. The success of vaccination programs is considered one of the greatest victories in modern medicine.

Safety and side effects

IPV has an excellent safety profile with side effects generally limited to minor redness or soreness at the injection site. OPV, being a live vaccine, carries a rare risk of causing vaccine-associated paralytic poliomyelitis, estimated at a few cases per million doses. There is also a risk of circulating vaccine-derived poliovirus emergence in areas with very low immunization coverage. These risks are carefully monitored by agencies including the Advisory Committee on Immunization Practices and are central to policy decisions regarding vaccine choice.

Global eradication efforts

The coordinated worldwide campaign to eliminate polio is led by the Global Polio Eradication Initiative, a partnership founded in 1988 involving the WHO, UNICEF, the Centers for Disease Control and Prevention, and Rotary International. The strategy relies on intensive surveillance, high routine immunization coverage, and supplementary immunization activities like mop-up vaccination in outbreak zones. Significant challenges remain, including reaching children in conflict zones like parts of Afghanistan and ensuring secure cold chain logistics for vaccine delivery. The ultimate goal is to certify global eradication, after which vaccination policies will be carefully managed by the World Health Assembly to prevent any future resurgence.

Category:Vaccines Category:Polio Category:Eradicated diseases